Stockscreener 앱 받기
15.73
2.36%
-0.38
시간 외 거래:
15.73
전일 마감가:
$16.11
열려 있는:
$16.31
하루 거래량:
546.19K
Relative Volume:
0.37
시가총액:
$1.62B
수익:
$54.55M
순이익/손실:
$-193.57M
주가수익비율:
-5.4429
EPS:
-2.89
순현금흐름:
$-181.86M
1주 성능:
-1.38%
1개월 성능:
-14.42%
6개월 성능:
+56.99%
1년 성능:
-9.13%
1일 변동 폭
$15.33
$16.37
1주일 범위
$15.33
$17.03
52주 변동 폭
$8.18
$22.50
누릭스 테라퓨틱스 Stock (NRIX) Company Profile
명칭
Nurix Therapeutics Inc
전화
(415) 660-5320
주소
1600 SIERRA POINT PKWY, BRISBANE
Compare NRIX vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NRIX
Nurix Therapeutics Inc
|
15.73 | 1.66B | 54.55M | -193.57M | -181.86M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
누릭스 테라퓨틱스 Stock (NRIX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-08 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-24 | 재개 | Truist | Buy |
| 2025-10-21 | 개시 | Mizuho | Outperform |
| 2025-03-17 | 개시 | Leerink Partners | Market Perform |
| 2024-12-10 | 개시 | BTIG Research | Buy |
| 2024-12-06 | 개시 | BMO Capital Markets | Outperform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-10-11 | 개시 | Jefferies | Buy |
| 2024-09-06 | 재개 | Robert W. Baird | Outperform |
| 2024-07-31 | 개시 | Truist | Buy |
| 2023-06-26 | 재개 | Oppenheimer | Outperform |
| 2023-03-09 | 개시 | Barclays | Overweight |
| 2023-02-28 | 개시 | Oppenheimer | Outperform |
| 2022-10-11 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-05-31 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-02-10 | 개시 | Wells Fargo | Equal Weight |
| 2021-12-29 | 개시 | H.C. Wainwright | Buy |
| 2021-10-14 | 개시 | SVB Leerink | Outperform |
| 2021-06-04 | 재개 | Robert W. Baird | Outperform |
| 2021-04-30 | 재개 | Piper Sandler | Overweight |
| 2021-04-30 | 개시 | RBC Capital Mkts | Outperform |
| 2021-04-14 | 개시 | Berenberg | Buy |
| 2020-11-19 | 개시 | Robert W. Baird | Outperform |
| 2020-08-18 | 개시 | JP Morgan | Overweight |
| 2020-08-18 | 개시 | Needham | Buy |
| 2020-08-18 | 개시 | Piper Sandler | Overweight |
| 2020-08-18 | 개시 | Stifel | Buy |
모두보기
누릭스 테라퓨틱스 주식(NRIX)의 최신 뉴스
Insider Sell: Christine Ring Sells Shares of Nurix Therapeutics Inc (NRIX) - GuruFocus
Nurix Therapeutics (NRIX) Is Down 7.4% After Pivotal Bexobrutideg Update and Wider 2025 Loss - Sahm
VIX Spike: Can Nurix Therapeutics Inc sustain its profitabilityGDP Growth & Weekly High Return Stock Forecasts - baoquankhu1.vn
Nurix Therapeutics (NRIX) Is Down 7.4% After Wider 2025 Losses And New ESOP Share ShelfWhat's Changed - Yahoo Finance
Stifel raised Nurix Therapeutics, Inc. (NRIX) price target to $35 and maintains buy ahead of 2026 catalysts - MSN
Behavioral Patterns of NRIX and Institutional Flows - Stock Traders Daily
Is Nurix Therapeutics Inc forming a bullish divergenceWeekly Trend Report & Free Risk Controlled Daily Trade Plans - baoquankhu1.vn
Nurix Therapeutics, Inc. (NRIX): A Bull Case Theory - Finviz
Stifel Raised Nurix Therapeutics, Inc. (NRIX) Price Target to $35 and Maintains Buy Ahead of 2026 Catalysts - Finviz
Research Analysts Offer Predictions for NRIX Q1 Earnings - MarketBeat
Published on: 2026-02-01 10:49:34 - baoquankhu1.vn
Nurix Therapeutics, Inc. (NASDAQ:NRIX) Just Reported Its Yearly Results And Analysts Are Updating Their Forecasts - 富途牛牛
HC Wainwright remains a buy on Nurix Therapeutics (NRIX) - MSN
Nurix Therapeutics, Inc. (NRIX) Stock Analysis: Unpacking A 70% Upside Potential - DirectorsTalk Interviews
Nurix Therapeutics Exposed to Significant Foreign Exchange Risk Amid Unhedged Currency Exposure - The Globe and Mail
Nurix Therapeutics chief legal officer Ring sells $73k in stock By Investing.com - Investing.com Nigeria
Nurix Therapeutics chief legal officer Ring sells $73k in stock - Investing.com UK
Houte Hans Van Sells 3,661 Shares of Nurix Therapeutics (NASDAQ:NRIX) Stock - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Insider Gwenn Hansen Sells 4,895 Shares - MarketBeat
H.C. Wainwright Remains a Buy on Nurix Therapeutics (NRIX) - Finviz
Nurix Therapeutics CSO Gwenn Hansen sells $81k in shares By Investing.com - Investing.com Canada
Nurix Therapeutics CFO Hans van Houte sells $61k in shares - Investing.com Canada
Big Picture: Can Artius II Acquisition Inc Equity Right be the next market leaderWeekly Stock Summary & Real-Time Market Sentiment Reports - baoquankhu1.vn
Should I buy Nurix Therapeutics Inc stock now2025 Technical Patterns & Weekly High Conviction Ideas - baoquankhu1.vn
Nurix Therapeutics (NRIX) Q4 Loss Highlights Ongoing Profitability Concerns Despite Revenue Progress - Sahm
Stock Analysis: Will Nurix Therapeutics Inc be affected by tariffsQuarterly Trade Summary & Weekly Breakout Opportunity Watchlist - baoquankhu1.vn
Momentum Shift: Can THTX expand into new marketsMarket Weekly Review & Fast Exit and Entry Strategy Plans - baoquankhu1.vn
HC Wainwright Raises Price Target for NRIX, Reaffirms Buy Rating - GuruFocus
Nurix Therapeutics price target raised to $35 from $33 at Stifel - TipRanks
Piper Sandler Raises Price Target on Nurix Therapeutics (NRIX) t - GuruFocus
Royal Bank Of Canada Issues Positive Forecast for Nurix Therapeutics (NASDAQ:NRIX) Stock Price - MarketBeat
NRIX: RBC Capital Raises Price Target and Maintains Outperform R - GuruFocus
NRIX: Stifel Raises Price Target to $35, Maintains 'Buy' Rating - GuruFocus
NRIX: Wells Fargo Lowers Price Target to $29, Maintains Overweig - GuruFocus
NRIX Analyst Jeet Mukherjee Reiterates Buy Rating, Target Stays at $30 | NRIX Stock News - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Earns "Buy" Rating from BTIG Research - MarketBeat
Nurix Therapeutics price target lowered to $29 from $30 at Wells Fargo - TipRanks
Nurix Therapeutics price target raised to $35 from $32 at Piper Sandler - TipRanks
NRIX: Needham Reiterates Buy Rating with Stable Price Target | N - GuruFocus
What 11 Analyst Ratings Have To Say About Nurix Therapeutics - Benzinga
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update - The Manila Times
A Look At Nurix Therapeutics (NRIX) Valuation As DAYBreak Phase 2 Trial Progresses - Sahm
Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Nurix (NRIX) Achieves Key Milestone with Q4 Revenue and Program Launch - GuruFocus
Nurix Therapeutics (NASDAQ:NRIX) Announces Quarterly Earnings Results - MarketBeat
Nurix Therapeutics (NASDAQ:NRIX) Stock Price Down 6.7%Time to Sell? - MarketBeat
Nurix Therapeutics Announces Initiation of DAYBreak™ Program for Bexobrutideg in Relapsed/Refractory CLL with Promising Phase 1 Results - Quiver Quantitative
Nurix Therapeutics, Inc. SEC 10-K Report - TradingView
Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q4 Revenue $13.6M, vs. FactSet Est of $13.4M - marketscreener.com
NRIX: Advanced pivotal CLL trials, grew revenue, and maintained strong cash reserves - TradingView
누릭스 테라퓨틱스 (NRIX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):